These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 29016454)
41. [Effects of ozurdex on intraocular pressure. A real life clinical practice study]. Jiménez-Gómez B; González-Montpetit M; Fonollosa Calduch A; Orive Bañuelos A; Valsero Franco S Arch Soc Esp Oftalmol; 2015 Sep; 90(9):421-5. PubMed ID: 25817950 [TBL] [Abstract][Full Text] [Related]
42. Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema. Choi MY; Kwon JW Sci Rep; 2020 Aug; 10(1):13736. PubMed ID: 32792579 [TBL] [Abstract][Full Text] [Related]
43. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Vasconcelos-Santos DV; Nehemy PG; Schachat AP; Nehemy MB Retina; 2008 Apr; 28(4):573-80. PubMed ID: 18398360 [TBL] [Abstract][Full Text] [Related]
44. Treatment of Non-infectious Uveitic Macular Edema with the Intravitreal Dexamethasone Implant. Nobre-Cardoso J; Champion E; Darugar A; Fel A; Lehoang P; Bodaghi B Ocul Immunol Inflamm; 2017 Aug; 25(4):447-454. PubMed ID: 27003221 [TBL] [Abstract][Full Text] [Related]
45. Intraocular pressure monitoring post intravitreal steroids: a systematic review. Kiddee W; Trope GE; Sheng L; Beltran-Agullo L; Smith M; Strungaru MH; Baath J; Buys YM Surv Ophthalmol; 2013; 58(4):291-310. PubMed ID: 23768920 [TBL] [Abstract][Full Text] [Related]
46. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials. Parrish RK; Campochiaro PA; Pearson PA; Green K; Traverso CE; Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):426-35. PubMed ID: 27183546 [TBL] [Abstract][Full Text] [Related]
47. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Haller JA; Bandello F; Belfort R; Blumenkranz MS; Gillies M; Heier J; Loewenstein A; Yoon YH; Jacques ML; Jiao J; Li XY; Whitcup SM; Ophthalmology; 2010 Jun; 117(6):1134-1146.e3. PubMed ID: 20417567 [TBL] [Abstract][Full Text] [Related]
49. [Tolerability and short-term efficacy of the Ozurdex® dexamethasone intravitreal implant for treatment of uveitic cystoid macular edema: A retrospective study of 52 injections performed at the Clermont-Ferrand teaching hospital]. Bernard Y; Bonnin N; Farguette F; Chiambaretta F J Fr Ophtalmol; 2016 Jan; 39(1):1-4. PubMed ID: 26616298 [TBL] [Abstract][Full Text] [Related]
50. Evaluation of the Effect of Intravitreal Dexamethasone (Ozurdex Garlı M; Aydın Kurna S; Açıkalın B; Çeviker A Turk J Ophthalmol; 2021 Dec; 51(6):365-372. PubMed ID: 34963264 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. Lei S; Lam WC Can J Ophthalmol; 2015 Jun; 50(3):236-41. PubMed ID: 26040225 [TBL] [Abstract][Full Text] [Related]
52. A Comparison of Ocular Complications after 0.7 mg Dexamethasone Implant versus 2 mg of Intravitreal Triamcinolone in Vitrectomized Eyes. Wakabayashi T; Liu CK; Anderson HE; Mahmoudzadeh R; Nguyen MK; Salabati M; Chiang A; Hsu J; Garg SJ; Spirn MJ Ophthalmol Retina; 2023 Jun; 7(6):480-488. PubMed ID: 36572383 [TBL] [Abstract][Full Text] [Related]
53. Baseline intraocular pressure: an independent risk factor in severe steroid-induced ocular hypertension after intravitreal dexamethasone implant. Cho WJ; Lee JM; Bae HW; Kim CY; Seong GJ; Choi W Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1231-1243. PubMed ID: 37930443 [TBL] [Abstract][Full Text] [Related]
54. Dexamethasone implant in pseudophakic and nonglaucomatous subgroup of diabetic macular edema patients: a real life experience. Ozkaya A; Alagoz C; Alagoz N; Gunes H; Yilmaz I; Perente I; Yazici AT; Taskapili M Eur J Ophthalmol; 2016 Jun; 26(4):351-5. PubMed ID: 26692061 [TBL] [Abstract][Full Text] [Related]
55. Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis. Sella R; Oray M; Friling R; Umar L; Tugal-Tutkun I; Kramer M Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1777-82. PubMed ID: 26228441 [TBL] [Abstract][Full Text] [Related]
56. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Zarranz-Ventura J; Carreño E; Johnston RL; Mohammed Q; Ross AH; Barker C; Fonollosa A; Artaraz J; Pelegrin L; Adan A; Lee RW; Dick AD; Sallam A Am J Ophthalmol; 2014 Dec; 158(6):1136-1145.e5. PubMed ID: 25217856 [TBL] [Abstract][Full Text] [Related]
57. Severe intraocular pressure response to periocular or intravitreal steroid treatment in Australia and New Zealand: data from the Australian and New Zealand Ophthalmic Surveillance Unit. Fitzgerald JT; Saunders L; Ridge B; White AJ; Goldberg I; Clark B; Mills RA; Craig JE Clin Exp Ophthalmol; 2015 Apr; 43(3):234-8. PubMed ID: 25214011 [TBL] [Abstract][Full Text] [Related]
58. The Efficiency of Intravitreal Dexamethasone Implants in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion. Unsal E; Eltutar K; Sultan P; Gungel H J Ocul Pharmacol Ther; 2015; 31(6):350-6. PubMed ID: 26133058 [TBL] [Abstract][Full Text] [Related]